

Journal of Visualized Experiments

Calibration-Free in-vitro Quantification of Protein Homo-Oligomerization Using Commercial Instrumentation and Free, Open Source Software --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58157R2
Full Title:	Calibration-Free in-vitro Quantification of Protein Homo-Oligomerization Using Commercial Instrumentation and Free, Open Source Software
Keywords:	Dimerization, calibration free spectroscopy, fluorescence fluctuation, number and brightness, Protein aggregation, single molecule microscopy
Corresponding Author:	S Dr. Padilla
Corresponding Author's Institution:	
Corresponding Author E-Mail:	spadilla@well.ox.ac.uk
First Author:	Rory Nolan
Other Authors:	Rory Nolan
	Luis A Alvarez
	Samuel C Griffiths
	Jonathan Elegheert
	Christian Siebold
Author Comments:	Thanks for the opportunity of re-submitting a second version of peer reviewed and corrected manuscript
Additional Information:	
Question	Response
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	

TITLE:

Calibration-Free *In-Vitro* Quantification of Protein Homo-Oligomerization Using Commercial Instrumentation and Free, Open Source Brightness Analysis Software

AUTHORS & AFFILIATIONS:

Rory Nolan¹, Luis A. Alvarez¹, Samuel C. Griffiths², Jonathan Elegheert², Christian Siebold² and Sergi Padilla-Parra^{1,2,3,4}

¹Cellular Imaging Group, Wellcome Centre Human Genetics, University of Oxford, UK.

²Division of Structural Biology, Wellcome Centre Human Genetics, University of Oxford, UK.

³Dynamic Structural Virology Group, Biocruces Health Research Centre, Barakaldo, Spain.

⁴IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.

Corresponding Author:

Sergi Padilla-Parra (spadilla@well.ox.ac.uk)

Email Addresses of Co-authors:

Rory Nolan (rory.nolan@hertford.ox.ac.uk)

Luis A. Alvarez (lalvarez@well.ox.ac.uk)

Samuel C. Griffiths (griffiths@strubi.ox.ac.uk)

Jonathan Elegheert (jelegheert@strubi.ox.ac.uk)

Christian Siebold (christian@strubi.ox.ac.uk)

KEYWORDS:

Dimerization, calibration free spectroscopy, fluorescence fluctuation, number and brightness, protein aggregation, single molecule microscopy

SUMMARY:

This protocol describes a calibration-free approach for quantifying protein homo-oligomerization *in vitro* based on fluorescence fluctuation spectroscopy using commercial light scanning microscopy. The correct acquisition settings and analysis methods are shown.

ABSTRACT:

Number and brightness is a calibration-free fluorescence fluctuation spectroscopy (FFS) technique for detecting protein homo-oligomerization. It can be employed using a conventional confocal microscope equipped with digital detectors. A protocol for the use of the technique *in vitro* is shown by means of a use case where number and brightness can be seen to accurately quantify the oligomeric state of mVenus-labelled FKBP12F36V before and after the addition of the dimerizing drug AP20187. The importance of using the correct microscope acquisition parameters and the correct data preprocessing and analysis methods are discussed. In particular, the importance of the choice of photobleaching correction is stressed. This inexpensive method can be employed to study protein-protein interactions in many biological contexts.

INTRODUCTION:

Protein-Protein interactions *in vitro*

Traditionally, crystallography and nuclear magnetic resonance experiments combined with cryo-electron microscopy (cryoEM) are the technologies chosen to accurately describe the three-dimensional architecture of proteins and to infer their function by scrutinizing their high resolution structural details. Proteins, however, are not static structures and can undergo a variety of conformational changes and vibrations in time and space. This is why structural information from crystallographic or CryoEM data needs to be complemented with other techniques (*e.g.*, molecular dynamics simulations and single molecule techniques): the function of a protein is related to its conformational changes and interactions, and this information is not present in a static structure. In order to probe for intra-molecular dynamics, techniques based on single molecule Forster Resonance Energy Transfer (smFRET) are very effective¹. These approaches are able to assess different subpopulations of molecules in complex media. This is very important, as these changes are rapid and occur during the acquisition of the data (*i.e.*, nanosecond to second range).

Two main approaches are commonly employed to detect and quantify these changes: proteins in solution and surface-immobilization. For the detection of inter-molecular interactions and in particular, the process of dimerization induced by ligands, smFRET is not always the best tool. Indeed, FRET depends not only on the distance (≈ 10 nm) but also on the orientation of the two dipoles (donor and acceptor, χ^2) and the overlap of the donor emission with the acceptor's absorption spectra², but perhaps this last condition is less important provided that the experimentalist can choose the right FRET couple. A particular disadvantage of smFRET for probing homo-dimerization comes from the labeling of the protein of interest: for hetero smFRET, dimerization can only be detected up to 50% (*i.e.*, hetero-FRET will only be able to detect donor-acceptor and acceptor-donor homo-dimers but not donor-donor or acceptor-acceptor, which is the other 50% of the dimers). The use of fluorescence correlation spectroscopy (FCS) and derivatives (FCCS, *etc.*³) to ascertain protein diffusion constants and binding constants *in vitro* is another alternative. These approaches are not able to fully quantify homo-dimerization either, as in FCS one measures concentration and diffusion, and the radius and diffusion coefficient of a diffusing particle are very poorly dependent on the molecular weight; for example a 10-fold increase in the molecular weight will only imply a 2.15 fold change in the diffusion coefficient⁴. In the case of two-color FCS or FCCS, only 50% of homo-dimers will be seen for the same reason as above. The most practical and quantitative approaches to detect homo-dimerization *in vitro* and *in vivo* are homo-FRET⁵ and number and brightness (N&B)⁶. Given the fact that homo-FRET requires specific instrumentation recovery of the anisotropy value (*i.e.*, optical elements/analyzers to recover the parallel and perpendicular polarization), N&B is presented here as a favorable technique to detect protein homo-dimerization and aggregation. It can be employed both *in vitro* and *in vivo* with a commercial set-up.

Number and Brightness

N&B has been recently reviewed⁷. That review focused on the application of the technique in live cells. It is worthwhile to reproduce the mathematical formalism here as these equations will be applied to the data collected *in vitro*. First, it is necessary to define some terms and mathematical quantities:

- An entity is a set of molecules which are bound together.
- The *brightness* ϵ of an entity is the number of photons it emits per unit time (per frame).
- n is the number of entities present.
- For a given pixel over the course of an image series, $\langle I \rangle$ is its mean intensity and σ^2 is the variance in its intensity.

Then, with photon-counting detectors and assuming mobile entities and no background,

$$N = \frac{\langle I \rangle^2}{\sigma^2} = \frac{\epsilon n}{1 + \epsilon}$$

$$B = \frac{\sigma^2}{\langle I \rangle} = 1 + \epsilon$$

where N is the *apparent number* and B is the *apparent brightness*. This results in

$$n = \frac{\langle I \rangle^2}{\sigma^2 - \langle I \rangle}$$

$$\epsilon = \frac{\sigma^2}{\langle I \rangle} - 1$$

Dalal *et al.*⁸ showed that with analog equipment, one needs three correction terms: the *S factor*, the background *offset*, and the *readout noise* σ_0^2 . Then, again assuming mobile entities,

$$N = \frac{(\langle I \rangle - \text{offset})^2}{\sigma^2 - \sigma_0^2} = \frac{\epsilon n}{1 + \epsilon}$$

$$B = \frac{\sigma^2 - \sigma_0^2}{\langle I \rangle - \text{offset}} = S(1 + \epsilon)$$

giving

$$n = \frac{(\langle I \rangle - \text{offset})^2}{\sigma^2 - \sigma_0^2 - S(\langle I \rangle - \text{offset})}$$

$$\epsilon = \frac{\sigma^2 - \sigma_0^2}{S(\langle I \rangle - \text{offset})} - 1$$

Note that the above equation for ϵ is different that given in Dalal *et al.*⁸ and a subsequent review.⁷ In Dalal *et al.* the S in the denominator was omitted due to a typo and this error was reproduced in the review. The equation above is the correct one. Instructions for measuring S , offset and σ_0^2 – together with an explanation of their meaning – are given by Dalal *et al.*⁸

The brightness ε is proportional to the oligomeric state of the diffusing entities: ε will be twice as big for dimers as it is for monomers, three times as big for trimers as it is for monomers, twice as big for hexamers as it is for trimers and so on. In this way, measuring the brightness ε , one can quantify any type of multimerization.

If there are a mixture of oligomeric states present, number and brightness is not capable of recovering the individual oligomeric states present. This is a limitation of the technique.

Detrend algorithm and nandb software

The importance of correcting for photobleaching has been previously stressed⁹. Photobleaching inevitably occurs during light microscopy experiments in time-lapse mode; both in live cells and *in vitro*. Many approaches have been described in the literature to correct for bleaching.⁷ The exponential filtering technique with automatic choice of detrending parameter τ is the current best. It is integrated into the free, open source software nandb⁹. Indeed, software that requires the user to manually choose their detrending parameter can lead to incorrect results because this parameter choice will likely be arbitrary and incorrect. The *automatic* algorithm inspects the data and determines the appropriate parameter for it, without the need for user intervention⁹. Even with the best choice of smoothing parameter, detrending has its limitations and works well only with photobleaching percentages lower than 25%, as shown with simulations⁹. Interestingly, when using the automatic detrending routine, its accuracy is such that one can work with low brightness values (even $B < 1.01$), and hence low intensities, and still be precise enough to quantify homo-dimerization.

Photobleaching also causes another problem: the presence of photobleached fluorophores in a multimer complex. This makes *e.g.*, a trimer appear like a dimer when one of the three units in the trimer is non-fluorescent. Hur and Mueller¹⁰ showed how to correct for this and this correction was also stressed in a subsequent review⁷. The nandb software includes this correction⁹.

The FKBP12F36V system

FKBP12F36V is a protein which does not naturally oligomerize but is known to dimerize upon the addition of the AP20187 drug (colloquially known as the BB dimerizing ligand)^{11,12}. This makes it an ideal test case for number and brightness: with labelled FKBP12F36V, a doubling of oligomeric state should be observed upon addition of BB.

PROTOCOL:

1. FKBP12F36V-mVenus Purification

1.1. Transform (DE3) pLysS cells with pET22b vector containing monomerized human FKBP12F36V¹² and N-terminal His6 and mVenus tags (vector available on request). Plate cells onto LB agar supplemented with 50 $\mu\text{g}/\text{mL}$ Ampicillin and 34 $\mu\text{g}/\text{mL}$ Chloramphenicol.

1.2. Transfer transformed colonies into 100 mL LB starter culture and grow for 16 - 20 hours at 37 °C with shaking.

1.3. Dilute dense starter culture ($OD_{600} > 1$) 1:100 in LB medium (2 x 500 mL batches) and grow for 2 – 3 hours to $OD_{600} = 0.6 - 0.8$ (37 °C, 200 rpm).

1.4. Cool cultures on ice. Induce with 250 μ M IPTG and grow for 16 – 20 hours at 21 °C, 200 rpm.

1.5. Harvest cells by centrifugation at 2000 x g for 20 minutes.

1.6. Resuspend pellet in 40 mL of IMAC buffer A (20 mM sodium phosphate pH 7.5, 500 mM NaCl, 3 mM imidazole, 1 mM β -mercaptoethanol) supplemented with EDTA-free protease inhibitors (1 tablet per cell pellet).

1.7. Sonicate cells (500 Watts, 20 kHz, 40% amplitude, 9 s on, 11 s off for 15 min) on ice and harvest soluble material by centrifugation at 20,000 x g.

1.8. Transfer soluble lysate to a conical flask and add 2 mL of resin (see **Table of Materials**). Incubate for 1 hour with 105 rpm rotation

Note: Nickel sepharose may also be used for this IMAC step.

1.9. Harvest resin and wash with 250 mL of IMAC buffer A followed by 500 mL of IMAC buffer B (20 mM sodium phosphate pH 7.5, 500 mM NaCl, 7 mM imidazole, 1 mM β -mercaptoethanol).

Note: Increase to 50 mM imidazole if using Nickel sepharose resin.

1.10. Elute His6-tagged protein using IMAC buffer C (20 mM sodium phosphate pH 7.5, 500 mM NaCl, 300 mM imidazole, 1 mM β -mercaptoethanol).

1.11. Inject onto a size exclusion column (see **Table of Materials**) equilibrated in 10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT. FKBP12F36V has its peak elution at 87.71 mL on the column we used.

1.12. Assess purity via SDS-PAGE and pool and concentrate as required.

2. Preparation of Multiwell Plate Array

2.1. Thaw the purified FKBP12F36V (or labeled protein of interest) from -80 °C.

2.2. Prepare a solution of 100 nM purified FKBP12F36V (medium, 10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT). Sonicate and centrifuge (quick spin of 13000 rpm) to prevent the formation of aggregates.

212
213 2.3. Pipette 100-200 μ L into an 8 well observation chamber with a glass bottom.

214
215 2.4. Add the BB dimerizer to final concentrations of 10, 20, 40, 80, 100, 150, 300, and 500 nM^{12,13}.

216
217 2.5. As a reference, prepare a solution of 100 nM of mVenus alone to evaluate potential
218 aggregation and precipitation effects and recover a brightness value for the monomer with the
219 same acquisition settings.

220 221 3. Calibration-free Confocal Acquisition

222
223 3.1. Start the confocal system (**Figure 1**). Any light scanning microscope confocal system
224 equipped with digital detectors or well-characterized analog detectors⁸, and capable of keeping
225 a constant dwell time for every pixel acquired would work.

226
227 3.2. Set the excitation beam path:

228
229 3.2.1. Turn on the 514 nm laser and set it at 20 – 100 nW Power at the exit of the objective (for
230 FKBP12F36V-mVenus).

231
232 3.2.2. Select the 63X1.4NA objective or a collar correction water immersion objective designed
233 for FCS.

234
235 3.2.3. Turn on one HyD, APD or calibrated PMT detector. Detectors capable of photon-counting
236 are preferable, as in this case, calculation of S , offset and σ_0^2 are unnecessary.

237
238 3.2.4. Select the emission window from 520 – 560 nm

239
240 3.2.5. Set the pinhole at 1 Airy unit for the corresponding emission \sim 545 nm.

241
242 3.2.6. Set the acquisition mode at 16 x 16 pixels

243
244 3.2.7. Set the pixel dwell time t_{dwell} such that it satisfies $t_{\text{frame}} \gg \tau_D \gg t_{\text{dwell}}$, where τ_D is the
245 residence time of the diffusing protein and t_{frame} is the frame rate. This corresponded to setting
246 the dwell time to \sim 13 μ s.

247
248 Note: Some commercial manufacturers had scanners that were not keeping the dwell-time per
249 pixel constant. This constancy is crucial for the method to work.

250
251 3.2.8. Set the pixel size at \sim 120 nm.

252
253 3.2.9. Select the *xyt* acquisition mode and select the number of frames to be acquired per
254 acquisition and well (for example 5,000).

3.2.10. If the system is equipped with high-throughput mode, introduce the coordinates of each well and the number of acquisitions per well to automate the process.

Note: Be careful to ensure the presence of a water dispenser for if using an immersion objective.

3.2.11. If the system is equipped with a perfusion system, load the BB solution and program the perfusion to start right-after the 5000th frame to evaluate the kinetics of dimerization while acquiring *e.g.*, 10,000 images.

3.3. Add a drop of oil into the oil immersion objective / water if utilizing a collar correction water immersion objective designed for FCS.

3.4. Mount the 8 well observation chamber into the stage.

3.5. Select the correct well and focus on the solution.

Note: IMPORTANT: Avoid focusing close to the bottom glass to avoid reflection and scattering. When focusing deeper into the solution, disconnect the automated focus option.

3.6. Start the acquisition and save the resulting stack of images in TIFF format.

4. Detrend and Brightness Analysis using the R Package nandb

4.1. As a preprocessing quality check, use ImageJ¹⁴ to take a look at the images and recover the intensity profile, as shown in **Figure 2a**. This is useful to determine whether or not too much photobleaching has occurred. If there is too much bleaching, the data is not suitable for further analysis.

Note: ImageJ can also be useful to convert images to TIFF from commercial formats. The nandb software described below can only work with TIFF files.

4.2. Download and install R and RStudio^{15,16}. It is best to download and install R first, then RStudio.

Note: What follows is a description of how to use the nandb R package. Knowledge of the R language is not required to use nandb, however it will make life easier.

4.3. Install the nandb package.

4.3.1. Open RStudio and in the console, type `install.packages("nandb")` and wait for the installation.

4.4. Get to know nandb

4.4.1. Review the manual¹⁷.

4.4.2. Review the built-in RStudio help for various functions. The most likely function to be used will be `brightness()`. View the help file for this function by typing `?brightness()` at the console.

4.5. Calculate brightness

4.5.1. Say one has an image file on the desktop called `img001.tif` (note that ``nandb`` only works with TIFF files). One can calculate the brightness of that image:

```
b <- brightness("~/Desktop/img001.tif", tau = "auto")
```

4.5.1.1. This assigns the brightness of the image to the variable `b` in R. The `tau = "auto"` ensures that the image is correctly detrended prior to brightness calculation. The most common thing to do from here is to calculate the mean or median brightness of the image. One can do this by typing `mean(b)` or `median(b)`. One can also write the brightness image to the desktop using

```
ijtiff::write_tif(b, "~/Desktop/whatever_img_name")
```

4.5.2. Say one has folder full of images `images_folder` on the desktop and one needs to calculate the brightnesses of these images and write the brightness images as TIFF files. Then see `?brightness_folder()`. This function processes a whole folder all at once:

```
brightness_folder("~/Desktop/images_folder", tau = "auto")
```

This is particularly good for those who have a software they prefer to R, because all of the files are processed in one single command, and then one can go on working with the output brightness TIFF images in their chosen software, be it ImageJ¹⁴, Python or something else.

REPRESENTATIVE RESULTS:

Detrending and monomeric brightness

Once the data has been acquired, one can start the brightness calculations to determine the oligomeric state of the protein of interest in the solution. Even if the effect of bleaching in solution may not be as drastic as it can be *in vivo*, the intensity trace will still probably not have stationary mean, possibly due to photophysical effects related to the fluorophore,¹⁸ but the reasons behind this are not fully understood. This has an impact when calculating the brightness; when trying to determine monomer–dimer transitions, this aspect is crucial. By applying the automatic detrend algorithm to the data shown in **Figure 2a**, the intensity trace is properly corrected, providing a more accurate value for the brightness of FKBP12F36V-mVenus in solution. Before addition of BB, without detrending, $B = 1.026$, whereas after detrending, $B = 1.005$ (**Figure 2b**).

Determination of FKBP12F36V -mVenus monomer-dimer transitions *in vitro*

Sequences of 20,000 images of purified FKBP12F36V -mVenus in 100 nM solution were acquired as specified in the protocol section. After 10,000 frames were acquired, the homodimerizer drug BB was added to the solution while acquiring. Each consecutive series of 5,000 frames was analyzed (**Figure 3**). The mean brightness 5 minutes after BB addition was $B = 1.010$, which is a 2-fold increase, indicating a FKBP12F36V dimer. The kinetics of the process is shown in **Figure 3b**; the delay between BB addition to full FKBP12F36V dimerization was approximately 2 minutes.

Identification of protein aggregates

A number of protein aggregates were detected both in a limited number of frames and also in the intensity trace (**Figure 4**). These aggregates occur naturally in solution when working with proteins and can be eliminated by sonicating and/or increasing the protein dilution. Nevertheless, in some biological problems, one needs to detect transitions between monomers and big aggregates. **Figure 4** shows an example where a FKBP12F36V protein aggregate diffused through the observation volume (images 16x16); for our previous calculations these data were discarded, however, one example is shown in **Figure 4** to show that these aggregates can be detected and characterized using the same settings and approach. At first sight, when evaluating the 5000 images, one can recover the average brightness for FKBP12F36V-mVenus treated with BB ($B = 1.010$). Viewing the raw brightness image, one can clearly see, though, a region of interest of approximately 8 pixels with a high value of $B \approx 1.080$. This region of interest coincides with a few frames at $t = 34 - 37$ s where a FKBP12F36V aggregate diffused around the observation area. The aggregate did not remain in the observation volume for long enough to accurately determine its size.

FIGURE AND TABLE LEGENDS:

Figure 1. Application of N&B to detect protein monomer-dimer transitions in solution. (a) Simplified optical path of a laser scanning microscope (LSM) equipped with a laser source (set at 514 nm in the case of mVenus labeled proteins) directed (blue arrows) toward an immersion objective (in our case a 63X1.4NA oil) illuminating a 100 nM solution of FKBP12F36V-mVenus solution. The emission fluorescence (green arrows) passes through a dichroic mirror and is directed toward a bandpass filter that cleans the emission light, and a pinhole set at 1 Airy unit situated right before a point digital detector capable of photon counting. **(b)** A confocal volume of illumination is scanned through 16 x 16 pixels illuminating single FKBP12F36V-mVenus molecules that enter and exit the Gaussian shape confocal volume producing an array of fluorescence intensity fluctuations. **(c)** Image series acquired over time.

Figure 2. Automatic detrending is needed to accurately measure a population of monomers in solution. (a) A stack of 5000 16 x 16 pixel images was acquired as described in Protocol section. The intensity of the first frame is shown together with the average time-resolved intensity profile, which shows long term fluctuations that might be related to bleaching and other solvent and/or

photophysics effects. Whatever the cause for these long-term fluctuations, they impact the brightness calculations and hence require detrending. Without automatic detrend, one gets $B = 1.026$, whereas after automatic detrending, $B = 1.005$. Also, the brightness without (left panels, second row) and with (right panels, second row) smooth filtering is shown. **(b)** The same data presented in (a) was detrended and the results in terms of intensity and brightness shown.

Figure 3. In-vitro N&B is able to resolve the transition between FKBP12F36V monomers and dimers in real time. The addition of the dimerizer drug BB resulted in a two-fold increase in true brightness right after 2 min (from 0.005 to 0.010 in true molecular brightness). **(a)** The intensity of the first frame is shown together with the mean intensity profile of the detrended image. The brightness without (left panels, second row) and with (right panels, second row) smooth filtering is shown. **(b)** Mean brightness is plotted (every 5000 frames) using the true molecular brightness ϵ . The dimerization occurs 2 minutes after BB addition ($t = 1$ min) at $t = 4$ min. The fitted curve is a sigmoidal function to stress the tendency toward dimerization after addition of the dimerizer drug (BB). Error bars represent the standard error of the brightness distribution at each time point.

Figure 4. In vitro N&B to resolve the size of protein aggregates in solution. **(a)** Time-resolved intensity detrended trace for the acquisition of FKBP12F36V-mVenus are shown together with brightness images (second row). **(b)** The time-resolved detrended intensity trace shows a maximum in intensity that is highlighted with a red dotted circle (top left panel). The first intensity frame that corresponds to this particular time ($t = 34$ seconds) is shown and a red arrow shows a FKBP12F36V-mVenus aggregate entering the illumination area. A closer look into the smoothed brightness image shows a region of interest that contains high oligomeric states and the rest of the image contains a mix between monomers and dimers with an average of $B = 1.008$.

DISCUSSION:

N&B is a technique to detect multimerization using commercial light scanning confocal microscopes equipped with digital detectors. This approach is quite attractive compared to single point FCS, FCCS and smFRET because it is calibration free and the brightness calculation is straightforward and concentration independent⁶. It is of major importance, however, to correct for bleaching and long-term intensity fluctuations before performing brightness calculations⁹; a slight increase of brightness due to bleaching and other artifacts could be misinterpreted as a change in oligomeric state (as seen in **Figure 2a**) if detrending is neglected or performed incorrectly. The use of the automatic detrend algorithm allows for accurate brightness calculations.

It is important, to follow a number of rules when acquiring the images. First, the residence time of the molecules in the confocal volume, and therefore their diffusion constant should be known in order to set the right parameters of the confocal system; the residence time of the labeled molecules needs to reside between the pixel dwell time and the frame time⁷. Choosing the right fluorophore is crucial. A bright and stable fluorophore is necessary for good signal to noise and minimal photobleaching. Laser power should be kept relatively low to avoid bleaching. Photon

counts of 1 or 2 per pixel are sufficient. Keeping counts low is also crucial to avoid detector pile-up. The technique copes with low photon budgets better than it copes with bleaching. In this protocol mVenus has been employed; which is a relatively bright fluorophore, comparable to eGFP¹⁹. An alternative is the use of nanoboosters that selectively target a fluorescent protein; these can be much brighter than traditional fluorophores²⁰.

In terms of hardware, digital photon-counting detectors make quantification easier, but N&B is possible with analog detectors, provided that one has recovered some acquisition parameters.⁸

Even though other approaches like anisotropy can detect homo-dimerization, with the advent of new software to simplify analysis, N&B stands alone as an accessible approach to detect and quantify protein interactions and oligomerization, both *in vitro* and in live cells.

ACKNOWLEDGMENTS:

This work has been supported by Wellcome Trust grant 105278/Z/14/2 to R.N. The Wellcome Trust Centre for Human Genetics is funded by Wellcome Trust Core Award 203852/Z/16/2. Work in the C.S. group is supported by Cancer Research UK (C20724/A14414), and the European Research Council under the European Union's Horizon 2020 Research and Innovation Programme Grant 647278.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

- 1 Voith von Voithenberg, L. & Lamb, D. C. Single pair forster resonance energy transfer: A versatile tool to investigate protein conformational dynamics. *BioEssays* **40**, doi:10.1002/bies.201700078 (2018).
- 2 Padilla-Parra, S., Auduge, N., Coppey-Moisán, M. & Tramier, M. Quantitative FRET analysis by fast acquisition time domain FLIM at high spatial resolution in living cells. *Biophysical Journal* **95**, 2976-2988, doi:10.1529/biophysj.108.131276 (2008).
- 3 Padilla-Parra, S., Auduge, N., Coppey-Moisán, M. & Tramier, M. Dual-color fluorescence lifetime correlation spectroscopy to quantify protein-protein interactions in live cell. *Microscopy Research and Technique*. **74**, 788-793, doi:10.1002/jemt.21015 (2011).
- 4 Muller, J. D., Chen, Y. & Gratton, E. Fluorescence correlation spectroscopy. *Methods in Enzymology* **361**, 69-92 (2003).
- 5 Tramier, M. & Coppey-Moisán, M. Fluorescence anisotropy imaging microscopy for homo-FRET in living cells. *Methods in Cell Biology* **85**, 395-414, doi:10.1016/s0091-679x(08)85017-0 (2008).
- 6 Digman, M. A., Dalal, R., Horwitz, A. F. & Gratton, E. Mapping the number of molecules and brightness in the laser scanning microscope. *Biophysical Journal* **94**, 2320-2332, doi:10.1529/biophysj.107.114645 (2008).
- 7 Nolan, R., Iliopoulou, M., Alvarez, L. & Padilla-Parra, S. Detecting protein aggregation and interaction in live cells: A guide to number and brightness. *Methods*,

doi:10.1016/j.ymeth.2017.12.001 (2017).

8 Dalal, R. B., Digman, M. A., Horwitz, A. F., Vetri, V. & Gratton, E. Determination of particle number and brightness using a laser scanning confocal microscope operating in the analog mode. *Microscopy Research and Technique* **71**, 69-81, doi:10.1002/jemt.20526 (2008).

9 Nolan, R. *et al.* nandb—number and brightness in R with a novel automatic detrending algorithm. *Bioinformatics*, doi:10.1093/bioinformatics/btx434 (2017).

10 Hur, K. H. *et al.* Quantitative Measurement of Brightness from Living Cells in the Presence of Photodepletion. *PLoS One* **9**, doi:10.1371/journal.pone.0097440 (2014).

11 Amara, J. F. *et al.* A versatile synthetic dimerizer for the regulation of protein–protein interactions. *Proceedings of the National Academy of Sciences of the United States of America* **94**, 10618-10623, doi:10.1073/pnas.94.20.10618 (1997).

12 Clackson, T. *et al.* Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. *Proceedings of the National Academy of Sciences of the United States of America* **95**, 10437-10442 (1998).

13 Rollins, C. T. *et al.* A ligand-reversible dimerization system for controlling protein–protein interactions. *Proceedings of the National Academy of Sciences of the United States of America* **97**, 7096-7101 (2000).

14 Schindelin, J., Rueden, C. T., Hiner, M. C. & Eliceiri, K. W. The ImageJ ecosystem: An open platform for biomedical image analysis. *Molecular Reproduction and Development* **82**, 518-529, doi:10.1002/mrd.22489 (2015).

15 R Core. R: A Language and Environment for Statistical Computing. (2017).


16 R Team. RStudio: Integrated Development Environment for R. (2016).

17 Nolan, R. nandb R package. <https://CRAN.R-project.org/package=nandb>. (2017).

18 Jung, G., Wiehler, J. & Zumbusch, A. The photophysics of green fluorescent protein: influence of the key amino acids at positions 65, 203, and 222. *Biophysical Journal* **88**, 1932-1947, doi:10.1529/biophysj.104.044412 (2005).


19 Shaner, N. C., Steinbach, P. A. & Tsien, R. Y. A guide to choosing fluorescent proteins. *Nature Methods* **2**, 905-909, doi:10.1038/nmeth819 (2005).

20 Butkevich, A. N. *et al.* Hydroxylated fluorescent dyes for live-cell labeling: synthesis, spectra and super-resolution STED. *Chemistry: A European Journal* **23**, 12114-12119, doi:10.1002/chem.201701216 (2017).




a



1.-Time-resolved FKBP12-mVenus [100nM] acquisition (raw)




b

2.-Time-resolved FKBP12-mVenus [100nM] acquisition (detrended)






a



b



Name of Material/ Equipment	Company
RosettaTM (DE3) pLysS cells	Novagen
Ampicillin	Sigma Aldrich
Chloramphenicol	Sigma Aldrich
LB starter culture	QIAGEN
LB medium	QIAGEN
IPTG	Sigma Aldrich
IMAC buffer	Medicago
EDTA-free protease inhibitors	Sigma Aldrich
TALON resin	Clonetech
Nickel sepharose	GE Healthcare
S200 16/60 column	GE Healthcare
Glass bottom 8 well observation dish	Ibidi

Catalog Number**Comments/Description**

70956-3

PubChem Substance ID 329824407

PubChem Substance ID: 24892250



PubChem Substance ID 329815691

09-1010-10

11873580001

80827



1 Alewife Center #200
 Cambridge, MA 02140
 tel. 617.945.9051
 www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT - UK

Title of Article:

CALIBRATION FREE In-Vitro QUANTIFICATION OF...

Author(s):

Rory Nalam, Luis Alvarez, Samuel Griffith, Jonathan Blegheart
 Christian Siebold and Sergi Padilla-Parras

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via:



Standard Access



Open Access

Item 2 (check one box):



The Author is NOT a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. Defined Terms. As used in this Article and Video License Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons

Attribution 3.0 Agreement (also known as CC-BY), the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by/3.0/us/legalcode>;

"Derivative Work" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JoVE" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*;

"Materials" means the Article and / or the Video; "Parties" means the Author and JoVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. Background. The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. Grant of Rights in Article. In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and

(c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in Section 3 above, the

ARTICLE AND VIDEO LICENSE AGREEMENT - UK

Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the

Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict

shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including,

without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or

damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

AUTHOR:

Name:

SERGI PADILLA-PARRA

Department:

WH9


Institution:

UNIVERSITY OF OXFORD

Article Title:

CALIBRATION-FREE In-Vitro Quant...

Signature:



Date:

15/03/2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy as a PDF to the JoVE submission site upon manuscript submission (preferred);
- 2) Fax the document to +1.866.381.2236; or
- 3) Mail the document to JoVE / Atn: JoVE Editorial / 1 Alewife Center Suite 200 / Cambridge, MA 02140

For questions, please email editorial@jove.com or call +1.617.945.9051.

MS # (internal use):

Dear Phillip,

Thanks for the opportunity to further increase the quality of our protocol. We have addressed and amended all your editorial comments (in bold in both the text and this point by point answer).

We hope this last version will be acceptable for publication in JoVe.

With best regards,

Dr. Sergi Padilla-Parra

Editorial comments:

1. 1.6: It's unclear what "Na/K pPhosphate" is.

We have now added the right recipe for the buffer

2. 1.7: Can you provide a few more details about sonicating (times, power, etc.).

Sonication: Sonics Vibra Cell 500 Watt, 20kHz. 40% amplitude, 9s on 11s off for 15 mins. Now added in the text

3. 1.11: Around where does this protein elute?

The protein has its peak elution at 87.71 mL on an s200 16/60.

4. 2.4: Can you clarify what 'Calculate the BB concentration' means?

As referred in the manuscript BB is the dimerizer drug. We mean that one needs to calculate the final volume in the observation chamber (now clarified in the text).

5. Figure 2: Are the images here the intensities, brightnesses, and mean intensity profiles of the first frame, as they are in Figure 3?

Yes

6. Figure 3b: What is the fitted curve?

The fitted curve is a sigmoidal function to stress the tendency toward dimerization after addition of the dimerizer drug (BB). We have included this info in the legend now.

7. Figure 4a: It looks like the bottom two frames are not the first frame, but rather a frame from 34-37 seconds.

The editor is right is this has been corrected

8. Figure 4b: You have $t = 47$ seconds in the legend, but it looks like it should be somewhere from 34 to 37 s.

The editor is right. This error came from the first version of the manuscript now corrected.

9. Note that text written in the Equation Editor will be formatted differently from the rest of the text; therefore it is recommended that all such inline text be rewritten in Calibri (the separated equations will look fine, though).

We have changed the Equation editor for Calibri in the text.

10. Please check that the access type (standard versus open) is correct. Generally, UK funding agencies require open access, but there are exceptions.

Thanks for the reminder. It is alright